中国P站

Obesity; Inflammation; Metabolic Syndrome; Adipose Tissue; Insulin Resistance; Gut Microbiota; Inflammasome; Extracellular Vesicles; Exosomes; Dietary Interventions

Introduction

Obesity is widely recognized as a major global health challenge, profoundly affecting metabolic health and increasing the risk of numerous chronic diseases. A central mechanism linking obesity to its diverse comorbidities is chronic low-grade inflammation. This systemic inflammatory state, often triggered by excess nutrient intake and adipose tissue expansion, perturbs metabolic homeostasis and drives the progression to conditions like type 2 diabetes, cardiovascular disease, and certain cancers [1].

This inflammatory environment is characterized by intricate cellular and molecular mechanisms, including the infiltration of immune cells into adipose tissue, the activation of specific inflammatory pathways, and the subsequent release of a cascade of pro-inflammatory cytokines. These processes represent crucial links between an obese state and the development of related health complications [1].

Central to orchestrating this obesity-associated inflammation and subsequent insulin resistance are adipose tissue macrophages (ATMs). As adipose tissue expands, it experiences an accumulation of ATMs, which polarize towards a pro-inflammatory M1 phenotype. This shift contributes significantly to the chronic low-grade inflammation observed, disrupting critical insulin signaling pathways not only in adipocytes but also in other vital metabolic tissues. Understanding the function of ATMs and developing strategies to target them offers promising avenues for therapeutic intervention in obesity-related metabolic dysfunction [2].

The gut microbiota also plays a pivotal, albeit complex, role in influencing adipose tissue inflammation within the context of obesity. Dysbiosis, an imbalance in the composition of gut microbes, can compromise the integrity of the gut barrier. This impairment leads to an increased translocation of bacterial products from the gut lumen into systemic circulation. These products then act as potent triggers for inflammatory responses within adipose tissue, contributing to both local and systemic inflammation and further exacerbating metabolic dysfunction. This intricate gut-adipose axis is emerging as a critical and exciting potential therapeutic target for mitigating obesity-related inflammation [3].

Another key mediator in the inflammatory cascade associated with obesity-related metabolic disorders is the inflammasome, a multiprotein complex. Various danger signals inherent to obesity, such as high levels of saturated fatty acids and cellular stress, are known activators of inflammasomes. The subsequent activation leads to the release of powerful pro-inflammatory cytokines, specifically IL-1β and IL-18. This release perpetuates chronic inflammation, which in turn contributes directly to the development of insulin resistance, hepatic steatosis, and other metabolic dysfunctions. Targeting these inflammasome pathways represents a significant area of research for future therapeutic interventions [4].

Adipose tissue is not only a site of inflammation but also a prime target for preventative strategies against obesity-associated metabolic syndrome. Research focuses on identifying and utilizing anti-inflammatory compounds to modulate the inflammatory environment within this tissue. These compounds, whether natural or synthetic, have the potential to influence immune cell activity, cytokine production, and oxidative stress pathways within adipose tissue. This area of research is critical for developing new therapeutic approaches to tackle obesity-driven metabolic dysfunction [5].

Chronic low-grade inflammation has been firmly established as a significant predictor for the progression from obesity to a full-blown metabolic syndrome. The persistent inflammatory state, often initiated by excessive nutrient intake and the expansion of adipose tissue, fundamentally disrupts metabolic homeostasis. This inflammatory milieu directly contributes to the characteristic features of metabolic syndrome, including insulin resistance, dyslipidemia, and hypertension. Recognizing inflammation as a critical factor underscores its importance in understanding the development and severity of metabolic syndrome [6].

Beyond individual metabolic health, the impact of obesity-related inflammation can extend across generations. Maternal obesity significantly influences adipose tissue inflammation in offspring. The intrauterine environment, shaped by a mother’s obese state, can program the developing offspring for heightened susceptibility to inflammation and metabolic dysregulation later in life. Potential mechanisms for this transgenerational effect include alterations in placental function, exposure to various inflammatory mediators, and epigenetic modifications, all contributing to adverse metabolic outcomes in the subsequent generation [7].

Immune cell-derived extracellular vesicles (EVs) also play a crucial role in mediating obesity-associated inflammation. These vesicles, released by various immune cells present in adipose tissue, act as transporters of pro-inflammatory molecules, microRNAs, and proteins to target cells. This intercellular communication mechanism actively exacerbates chronic inflammation within the adipose tissue microenvironment. Consequently, EVs are being investigated as potential biomarkers for obesity-related metabolic diseases and as novel therapeutic targets [8].

Moreover, dietary interventions offer a practical and effective strategy for mitigating adipose tissue inflammation in obesity. Specific dietary patterns, such as the Mediterranean diet, ketogenic diets, or diets rich in polyphenols and omega-3 fatty acids, can profoundly modulate the inflammatory response within adipose tissue. The underlying mechanisms include beneficial effects on gut microbiota composition, alterations in immune cell polarization, and direct anti-inflammatory pathways. These nutritional approaches provide valuable insights for managing obesity-related inflammation through lifestyle modifications [9].

Finally, exosomes, which are nanoscale extracellular vesicles secreted by various cell types including adipocytes and immune cells, contribute significantly to obesity-induced inflammation and insulin resistance. These exosomes carry distinct molecular cargo, such as proteins, lipids, and nucleic acids, enabling them to influence intercellular communication. Their role in propagating inflammatory signals and fostering the development of metabolic dysfunction suggests that exosomes could serve as novel therapeutic targets or diagnostic biomarkers in the ongoing battle against obesity-related diseases [10].

Description

Obesity is intricately linked with systemic low-grade inflammation, a phenomenon now understood to be a key driver in the development and progression of numerous chronic diseases. This includes serious conditions like type 2 diabetes, cardiovascular disease, and various cancers [1]. The underlying mechanisms are complex, involving immune cell infiltration into adipose tissue, activation of specific inflammatory pathways, and the release of pro-inflammatory cytokines that perpetuate a state of chronic inflammation. This persistent inflammatory environment fundamentally perturbs metabolic homeostasis, making chronic low-grade inflammation a major predictor for the progression of obesity to metabolic syndrome [1, 6]. The cumulative effect of this inflammatory state directly contributes to core features of metabolic syndrome such as insulin resistance, dyslipidemia, and hypertension.

Adipose tissue itself is not just a storage site for energy but an active endocrine organ, playing a critical role in orchestrating obesity-associated inflammation and subsequent insulin resistance. In states of obesity, adipose tissue expands, leading to the accumulation of adipose tissue macrophages (ATMs). These ATMs undergo a phenotypic shift, polarizing towards a pro-inflammatory M1 phenotype. This M1 polarization is a significant contributor to the chronic low-grade inflammation that disrupts insulin signaling in adipocytes and other metabolically active tissues. Consequently, adipose tissue is seen as a crucial target for preventing obesity-associated metabolic syndrome, with ongoing research exploring various natural and synthetic anti-inflammatory compounds. These compounds aim to modulate immune cell activity, cytokine production, and oxidative stress within adipose tissue, offering therapeutic potential [2, 5].

The gut microbiota emerges as another crucial player in this complex interplay. An imbalance in gut microbial composition, termed dysbiosis, can compromise the integrity of the gut barrier. This impaired barrier function allows for increased translocation of bacterial products from the gut into the systemic circulation. Once translocated, these bacterial products trigger potent inflammatory responses specifically within adipose tissue, contributing to both localized and systemic inflammation and metabolic dysfunction. This highlights the "gut-adipose axis" as a potential therapeutic target, suggesting that interventions aimed at restoring microbial balance could mitigate inflammation and improve metabolic health [3].

Cellular and molecular mediators of inflammation are also central to obesity-related disorders. The inflammasome, a multiprotein complex, acts as a pivotal hub. It becomes activated by various danger signals associated with obesity, such as high levels of saturated fatty acids and cellular stress. Upon activation, inflammasomes orchestrate the release of potent pro-inflammatory cytokines, specifically IL-1β and IL-18. This cytokine release drives chronic inflammation, directly contributing to conditions like insulin resistance and hepatic steatosis. Moreover, immune cells within adipose tissue release extracellular vesicles (EVs) and exosomes. These nanoscale vesicles carry pro-inflammatory molecules, microRNAs, and proteins, facilitating intercellular communication and thereby exacerbating chronic inflammation. EVs and exosomes are increasingly recognized as critical communicators in the adipose tissue microenvironment and hold promise as potential biomarkers or therapeutic targets for obesity-related metabolic diseases [4, 8, 10].

Finally, the broader implications of obesity-related inflammation extend to therapeutic interventions and even intergenerational impacts. Dietary strategies offer a practical approach to mitigating adipose tissue inflammation. Specific dietary patterns, including Mediterranean diets, ketogenic diets, and those rich in polyphenols and omega-3 fatty acids, can modulate the inflammatory response through various mechanisms, such as influencing gut microbiota, immune cell polarization, and direct anti-inflammatory pathways. Such nutritional insights are vital for managing obesity-related inflammation [9]. Additionally, maternal obesity can program the offspring for increased susceptibility to inflammation and metabolic dysregulation later in life. The intrauterine environment, affected by maternal obesity, can induce changes in placental function, expose the fetus to inflammatory mediators, and lead to epigenetic modifications, thereby contributing to adverse metabolic outcomes in the next generation. This emphasizes the wide-reaching effects and the need for comprehensive approaches to address obesity and its inflammatory consequences [7].

Conclusion

Obesity triggers systemic low-grade inflammation, a critical factor in developing chronic conditions like type 2 diabetes, cardiovascular disease, and certain cancers. This inflammation involves intricate cellular and molecular mechanisms, including immune cell infiltration in adipose tissue, activation of inflammatory pathways, and the release of pro-inflammatory cytokines. Adipose tissue macrophages (ATMs) play a key role, polarizing towards a pro-inflammatory M1 phenotype in expanding adipose tissue, which disrupts insulin signaling. The gut microbiota also influences this process; dysbiosis impairs gut barrier function, leading to bacterial product translocation and inflammatory responses in adipose tissue. Furthermore, inflammasomes, activated by danger signals like saturated fatty acids, mediate the release of pro-inflammatory cytokines such as IL-1β and IL-18, driving chronic inflammation and metabolic dysfunctions. Adipose tissue is a significant therapeutic target, with various natural and synthetic anti-inflammatory compounds showing promise in modulating immune cell activity and cytokine production. Chronic low-grade inflammation acts as a major predictor for the progression from obesity to metabolic syndrome. Immune cell-derived extracellular vesicles (EVs) and exosomes also exacerbate inflammation by transporting pro-inflammatory molecules between cells. Dietary interventions, including Mediterranean and ketogenic diets, can mitigate adipose tissue inflammation by affecting gut microbiota and immune cell polarization. Maternal obesity can even program offspring for increased susceptibility to inflammation and metabolic dysregulation, highlighting the broad impact of this condition.

References

1. Hongwei R, Shaoxiang X, Chunyan L (2022) .Int J Obes 46:477-486.

   , ,

2. Xiaoyu H, Shuang L, Man H (2022) .Front Immunol 13:933743.

   , ,

3. Yiming T, Yanan X, Meiyi Z (2021) .Front Physiol 12:670491.

   , ,

4. Xiaojun X, Xiaoguang L, Yan Z (2022) .Int J Mol Sci 23:16041.

   , ,

5. Angela C, Manuel C, José MC (2022) .Int J Mol Sci 23:3148.

   , ,

6. Francesco Z, Micol L, Sonia N (2022) .Int J Mol Sci 23:6283.

   , ,

7. Robbe VB, Eva VH, Benedicte YDW (2021) .Int J Mol S-ci 23:31.

   , ,

8. Dongting W, Xingchen L, Qian Z (2022) .Front Immunol 13:951239.

   , ,

9. Francesco Z, Micol L, Sonia N (2023) .Cells 12:2575.

   , ,

10. Xiaojun X, Caiyan J, Yanyan Z (2023) .Int J Mol Sci 24:5948.

    , ,